寄端霉素 ,(1aR,3Z,13S,14S,15aR)-9,13,14-trihydroxy-11-methoxy-6-methyl-5,6,13,14,15,15a-hexahydro-2H-oxireno[h][2]benzoxacyclotetradecine-2,8(1aH)-dione ,≥98% (HPLC)
产品编号:SIGMA-H1667| CAS NO:76958-67-3| 分子式:C19H22O8| 分子量:378.3732
Hypothemycin 是由真菌产生的聚酮化合物,是一种多激酶抑制剂,对 VEGFR2/VEGFR1,MEK1/MEK2,FLT-3,PDGFRβ/PDGFRα 和 ERK1/ERK2 的 Ki 值分别为 10/70 nM,17/38 nM, 90 nM,900 nM/1.5 μM 和 8.4/2.4 μM。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
英文名称 | (1aR,3Z,13S,14S,15aR)-9,13,14-trihydroxy-11-methoxy-6-methyl-5,6,13,14,15,15a-hexahydro-2H-oxireno[h][2]benzoxacyclotetradecine-2,8(1aH)-dione | |||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CAS编号 | 76958-67-3 | |||||||||||||||||||||||||||||||||||||||||||||||
产品描述 | Hypothemycin 是由真菌产生的聚酮化合物,是一种多激酶抑制剂,对 VEGFR2/VEGFR1,MEK1/MEK2,FLT-3,PDGFRβ/PDGFRα 和 ERK1/ERK2 的 Ki 值分别为 10/70 nM,17/38 nM, 90 nM,900 nM/1.5 μM 和 8.4/2.4 μM。 | |||||||||||||||||||||||||||||||||||||||||||||||
外观性状 | Solid | |||||||||||||||||||||||||||||||||||||||||||||||
溶解性 | DMSO: soluble | |||||||||||||||||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro:
DMSO : 100 mg/mL (264.29 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| |||||||||||||||||||||||||||||||||||||||||||||||
体外研究 | Hypothemycin inhibits eosinophilic EOL1 cell carrying mutations in FIP1L1-PDGFRα, acute myeloid leukemia MV-4-11 cell carrying mutations in FLT3-ITD, melanoma COLO829 cell carrying mutations in BRAF V600E, HUVEC cell carrying mutations in VEGFR, mastocytoma P815 cell carrying mutations in c-KIT D814Y, NSCLC A459 cell carrying mutations in KRAS, and ovarian SKOV-3 cell carrying mutations in HER2 with IC50s of 0.4 nM, 6 nM, 50 nM, 70 nM, 370 nM, 6.0 μM, and 7.0 μM, respectively。 | |||||||||||||||||||||||||||||||||||||||||||||||
体内研究 | Hypothemycin (10 mg/kg) kills T. brucei in infected mice, completely curing the infection in one third of animals, although high doses of Hypothemycin (>10 mg/kg) leads to side effects. XIYU has not independently confirmed the accuracy of these methods. They are for reference only.
| |||||||||||||||||||||||||||||||||||||||||||||||
细胞实验 | 生物活性Hypothemycin, one of the highly oxygenated analogues in the group of 14-membered resorcylic acid lactones (RAL), has minor antifungal and cytotoxic activity and exhibits an in vitro anti-malarial activity with an IC50 of 2.2 μg/mL. Hypothemycin is also reported to selectively and irreversibly inhibit protein kinases that contain a conserved cysteine residue (Cys166) that is located within the ATP-binding domain. Though this group accounts for less then 10% of all identified kinases, there are several targets implicated in aberrant cellular proliferation such as ERKs, MEK, FMS-like tyrosine kinase protein (FLT), and platelet-derived growth factor receptors (PDGFR). In cell culture, hypothemycin displays potent cytotoxicity against cancer cell lines that are dependent on certain activating kinase mutations. Additionally, hypothemycin demonstrates significant tumor growth inhibition in at least three separate murine xenograft models. Hypothemycin also inhibits the production of several cytokines such as IL2, IL6, IFNγ, and TNFα. | |||||||||||||||||||||||||||||||||||||||||||||||
动物实验 | 储备液配制*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
不同实验动物依据体表面积的等效剂量转换表(参考来源于公开文献)
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。 | |||||||||||||||||||||||||||||||||||||||||||||||
储存条件 | 储存条件: -20°C 运输方式: 冰袋运输,根据产品的不同,可能会有相应调整。 |
相关文档
化学品安全说明书(MSDS)
下载MSDS质检证书(COA)
相关产品